DE69431301D1 - Verfahren zur diagnose von störungen durch bestimmung der expression von gage-tumorabstossungsantigen-vorläufern - Google Patents

Verfahren zur diagnose von störungen durch bestimmung der expression von gage-tumorabstossungsantigen-vorläufern

Info

Publication number
DE69431301D1
DE69431301D1 DE69431301T DE69431301T DE69431301D1 DE 69431301 D1 DE69431301 D1 DE 69431301D1 DE 69431301 T DE69431301 T DE 69431301T DE 69431301 T DE69431301 T DE 69431301T DE 69431301 D1 DE69431301 D1 DE 69431301D1
Authority
DE
Germany
Prior art keywords
precisors
repeller
antique
expression
determining
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69431301T
Other languages
English (en)
Other versions
DE69431301T2 (de
Inventor
Den Eynde Benoit Van
Thierry Boon-Falleur
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ludwig Institute for Cancer Research New York
Original Assignee
Ludwig Institute for Cancer Research New York
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ludwig Institute for Cancer Research New York filed Critical Ludwig Institute for Cancer Research New York
Publication of DE69431301D1 publication Critical patent/DE69431301D1/de
Application granted granted Critical
Publication of DE69431301T2 publication Critical patent/DE69431301T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Dental Tools And Instruments Or Auxiliary Dental Instruments (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Measurement Of The Respiration, Hearing Ability, Form, And Blood Characteristics Of Living Organisms (AREA)
  • Measuring And Recording Apparatus For Diagnosis (AREA)
  • Magnetic Resonance Imaging Apparatus (AREA)
DE69431301T 1993-07-22 1994-07-13 Verfahren zur diagnose von störungen durch bestimmung der expression von gage-tumorabstossungsantigen-vorläufern Expired - Lifetime DE69431301T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US9603993A 1993-07-22 1993-07-22
US08/250,162 US5610013A (en) 1993-07-22 1994-05-27 Method for diagnosing a disorder by determining expression of gage tumor rejection antigen precursors
PCT/US1994/007878 WO1995003422A1 (en) 1993-07-22 1994-07-13 Method for diagnosing a disorder by determining expression of gage tumor rejection antigen precursors

Publications (2)

Publication Number Publication Date
DE69431301D1 true DE69431301D1 (de) 2002-10-10
DE69431301T2 DE69431301T2 (de) 2003-07-31

Family

ID=22254881

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69431301T Expired - Lifetime DE69431301T2 (de) 1993-07-22 1994-07-13 Verfahren zur diagnose von störungen durch bestimmung der expression von gage-tumorabstossungsantigen-vorläufern

Country Status (14)

Country Link
US (1) US5610013A (de)
EP (1) EP0711355B1 (de)
JP (1) JP3641692B2 (de)
KR (1) KR100281178B1 (de)
CN (1) CN1059465C (de)
AT (1) ATE223435T1 (de)
AU (1) AU677687B2 (de)
CA (1) CA2167692C (de)
DE (1) DE69431301T2 (de)
FI (1) FI960268A0 (de)
NO (1) NO960158L (de)
NZ (1) NZ269435A (de)
TW (1) TW498104B (de)
WO (1) WO1995003422A1 (de)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5648226A (en) * 1993-07-22 1997-07-15 Ludwig Institute For Cancer Research Isolated peptides derived from tumor rejection antigens, and their use
US6013481A (en) * 1993-07-22 2000-01-11 Ludwig Institute For Cancer Research Isolated, nucleic acid molecules which code for gage tumor rejection antigen, the tumor rejection antigen, and uses thereof
US6939707B2 (en) * 1993-07-22 2005-09-06 Ludwig Institute For Cancer Research Isolated nucleic acid molecules which encode GAGE genes and uses thereof
US5858689A (en) * 1993-07-22 1999-01-12 Ludwig Institute For Cancer Research Isolated peptides derived from the gage tumor rejection antigen precursor and uses thereof
EP0910646A1 (de) * 1996-06-25 1999-04-28 The Ludwig Institute for Cancer Research Glykogen phopshorylase krebsantigen aus dem gehirn
ZA98656B (en) 1997-01-27 1998-08-17 Ludwig Inst Cancer Res Lage-1 tumer associated nucleic acids
US5879892A (en) 1997-04-25 1999-03-09 Ludwig Institute For Cancer Research Leukemia associated genes
AU3587599A (en) * 1997-11-28 1999-06-16 Invitrogen Corporation Single chain monoclonal antibody fusion reagents that regulate transcript ion in vivo
US5905145A (en) * 1998-03-06 1999-05-18 Ludwig Institute For Cancer Research Isolated nucleic acid molecules which encode TAGE molecules, and uses thereof
US7001999B1 (en) * 1998-04-15 2006-02-21 Ludwig Institute For Cancer Research Tumor associated nucleic acids and uses therefor
US6245525B1 (en) 1998-07-27 2001-06-12 Ludwig Institute For Cancer Research Tumor associated nucleic acids and uses therefor
WO1999054466A2 (en) * 1998-04-20 1999-10-28 Fei Huang Colon cancer-associated antigens and their diagnostic and therapeutic uses
US6140050A (en) * 1998-06-26 2000-10-31 Ludwig Institute For Cancer Research Methods for determining breast cancer and melanoma by assaying for a plurality of antigens associated therewith
US6509172B1 (en) * 1998-09-30 2003-01-21 Ludwig Institute For Cancer Research Isolated, truncated nucleic acid which are members of the gage, and uses thereof
JP2003512057A (ja) 1999-10-19 2003-04-02 ルードヴィッヒ インスティテュート フォー キャンサー リサーチ Ｍａｇｅ−ａ１２抗原ペプチド及びその利用
AU2001229682A1 (en) 2000-01-21 2001-07-31 Cornell Research Foundation Inc. Small cell lung cancer associated antigens and uses therefor
WO2001061009A2 (en) * 2000-02-15 2001-08-23 Curagen Corporation Polypeptides and nucleic acids encoding same
EP1605045A3 (de) * 2000-02-15 2006-03-01 Curagen Corporation Polypeptide und dafür kodierende Nukleinsäure
US7470428B2 (en) 2002-01-30 2008-12-30 The Brigham And Women's Hospital, Inc. Compositions and methods related to TIM-3, a Th1-specific cell surface molecule
US7311914B2 (en) * 2002-08-13 2007-12-25 Ludwig Institute For Cancer Research MAGE-A4 antigenic peptides and uses thereof
MXPA05002455A (es) * 2002-09-06 2005-06-03 Mannkind Corp Secuencias de epitopes.
US7178491B2 (en) * 2003-06-05 2007-02-20 Caterpillar Inc Control system and method for engine valve actuator
ATE546153T1 (de) * 2003-06-17 2012-03-15 Mannkind Corp Kombinationen von tumor-assoziierten antigenen zur behandlung von verschiedenen krebstypen
US20060008468A1 (en) * 2004-06-17 2006-01-12 Chih-Sheng Chiang Combinations of tumor-associated antigens in diagnostics for various types of cancers
US20060159689A1 (en) * 2004-06-17 2006-07-20 Chih-Sheng Chiang Combinations of tumor-associated antigens in diagnostics for various types of cancers
CN101057145B (zh) * 2004-06-23 2014-10-22 得克萨斯系统大学评议会 使用双粒子复合体检测生物分子的方法和组合物
AU2005321904B2 (en) * 2004-12-29 2012-07-12 Mannkind Corporation Methods to elicit, enhance and sustain immune responses against MHC class I-restricted epitopes, for prophylactic or therapeutic purposes
CA2592968A1 (en) * 2004-12-29 2006-07-06 Mannkind Corporation Use of compositions comprising various tumor-associated antigens as anti-cancer vaccines
SG162817A1 (en) 2005-06-17 2010-07-29 Mannkind Corp Methods and compositions.to elicit multivalent immune responses against dominant and subdominant epitopes, expressed on cancer cells and tumor stroma
EP3238782A3 (de) * 2010-04-06 2018-01-03 ExoCyte Therapeutics Pte, LTD Verfahren zur behandlung von karzinomen

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4105538A (en) * 1977-01-21 1978-08-08 Mattox William J Process for the refining of used motor oils and products thereof
US5342774A (en) * 1991-05-23 1994-08-30 Ludwig Institute For Cancer Research Nucleotide sequence encoding the tumor rejection antigen precursor, MAGE-1
DE4238416A1 (de) * 1992-11-13 1994-05-19 Max Planck Gesellschaft Bestimmung von Peptidmotiven auf MHC-Molekülen

Also Published As

Publication number Publication date
EP0711355A1 (de) 1996-05-15
EP0711355B1 (de) 2002-09-04
NO960158L (no) 1996-01-22
JP3641692B2 (ja) 2005-04-27
FI960268A (fi) 1996-01-19
AU7332294A (en) 1995-02-20
JPH09504165A (ja) 1997-04-28
US5610013A (en) 1997-03-11
FI960268A0 (fi) 1996-01-19
CA2167692C (en) 2009-07-07
TW498104B (en) 2002-08-11
AU677687B2 (en) 1997-05-01
KR100281178B1 (ko) 2001-04-02
CA2167692A1 (en) 1995-02-02
WO1995003422A1 (en) 1995-02-02
CN1127532A (zh) 1996-07-24
EP0711355A4 (de) 1998-05-06
ATE223435T1 (de) 2002-09-15
NO960158D0 (no) 1996-01-15
CN1059465C (zh) 2000-12-13
NZ269435A (en) 1997-11-24
DE69431301T2 (de) 2003-07-31

Similar Documents

Publication Publication Date Title
DE69431301D1 (de) Verfahren zur diagnose von störungen durch bestimmung der expression von gage-tumorabstossungsantigen-vorläufern
ZA958039B (en) Isolated nucleic acid molecule coding for tumor rejection antigen precursor dage and uses thereof
FI956019A (fi) Eristettyjä peptidejä, jotka muodostavat komplekseja MHC-molekyyli HLA-C-klooni-10:n kanssa, ja niiden käyttö
ES487106A0 (es) Un metodo para producir al menos un polipeptido que muestra antigenicidad de hbv
DE69617440D1 (de) Isolierte nukleinsäuremoleküle, peptide die mit hla-a2 moleküle (mhc) komplexe bilden, sowie deren verwendungen
DE69020376D1 (de) Verfahren zur Herstellung von Mono- oder Dicarbonsäure-Stoffen, die durch langkettige Kohlenwasserstoffe substituiert sind.
DE3866558D1 (de) Verfahren zur herstellung von 1,1,1-trifluor-2,2-dichloraethan durch hydrofluorierung in gegenwart von katalysatoren.
DK0690675T3 (da) Nukleinsyre, der koder for en tumorafstödningsantigenprecursor
DE3576329D1 (de) Verfahren zur herstellung von 18f-markierten organischen verbindungen durch nukleophilen austausch.
ATE234858T1 (de) Isolierte und verkürzte nukleinsäuremoleküle kodierend für gage-tumorabstossungsantigen
NZ332369A (en) Isolated nucleic acid molecules which code for GAGE tumor rejection antigen, the tumor rejection antigen, and uses thereof
DE3681033D1 (de) Katalytisches verfahren zur herstellung von fluoraomatischen verbindungen mittels n-sek-alkylpyridiniumsalze.
DE69001623D1 (de) Verfahren zur herstellung von fluor-oxy-fluorsulfonylverbindungen durch direkte fluorierung von fluor-beta-sultonen.
DE69032526D1 (de) cDNS-FRAGMENT, DAS FÜR EIN INTERFERON-ALPHA-REZEPTOR-GEN KODIERT UND VERFAHREN ZUR HERSTELLUNG EINES ENTSPRECHENDEN PROTEINS
AT348763B (de) Verfahren zur herstellung von durch sulfogruppen modifizierten, hochdispersen harnstoff-formaldehyd-kondensationspolymeren
DE3777596D1 (de) Verfahren zur herstellung von 2-nitro-5-phenoxy-n-alkylsulfonylbenzamiden durch nitrierung.
DE69521281D1 (de) Verfahren zur Herstellung von menschlichem oder humanem Matrilysin mittels rekombinanter DNA.
TW372973B (en) Isolated, truncated nucleic acid molecules which code for gage tumor rejection antigen, the tumor rejection antigen, and uses thereof
DE58904746D1 (de) Antikoerper, verfahren zu ihrer herstellung, klone zur erzeugung der antikoerper sowie verwendung der antikoerper zur diagnose und therapie von tumoren.
ATE90793T1 (de) Antikoerper, verfahren zu ihrer herstellung, klone zur erzeugung der antikoerper sowie verwendung der antikoerper zur diagnose und therapie von tumoren.
ATA11674A (de) Verfahren zur herstellung von gitterrosten, sowie gitterrost hergestellt nach diesem verfahren
EP0264790A3 (de) Neue Hefeexpressionsvektoren für IFN-omega, Verfahren zu ihrer Herstellung und deren Verwendung

Legal Events

Date Code Title Description
8364 No opposition during term of opposition